Purpose To evaluate the reproducibility and interuser agreement of measurements of choroidal neovascularisation in optical coherence tomography angiography (OCTA).
Design Prospective non-interventional study.
Methods Consecutive patients, presenting with neovascular age-related macular degeneration (AMD), underwent two sequential OCTA examinations (AngioVue, Optovue, Fremont, California, USA), performed by the same trained examiner. Neovascular lesion area was then measured on both examinations in the choriocapillaris automatic segmentation by two masked readers, using the semiautomated measuring software embedded in the instrument. Two measuring features were used: the first corresponding to the total manually contoured lesion area with the flow draw tool (select area) and the second to the total area of solely vessels with high flow within the lesion (vessel area). These measurements were then compared in order to assess both the reproducibility of OCTA examination and the interuser agreement with the embedded software.
Results Forty-eight eyes of 46 patients (77.4 mean age,+/-8.2 SD, range from 62 to 95 years old, eight men, 38 women) were included in our study. Mean choroidal neovascularisation area was of 0.72+/-0.7 mm2 for the first measurement and 0.75+/-0.76 mm2 for the second measurement; difference between the first and the second measurement was 0.03 mm2. Intrauser agreement was of 0.98 (CI 0.98 to 0.99) for both ‘vessel area’ and ‘select area’ features. Interuser agreement was of 0.98 (CI 0.97 to 0.99) for ‘select area’ and ‘vessel area’ features.
Conclusion Our data suggest that OCTA provide reproducible imaging for evaluation of the neovascular size in the setting of AMD.
- OCT angiography
- neovascular AMD.
Statistics from Altmetric.com
Contributors FA and AM contributed to the conception and design of the study, writing, drafting and revising process. OS and VC were involved in execution of the study, revising and drafting process. CJ, FA and AM were involved in data collection, interpretation and statistical analysis. EHS participated in all the main aspects of the study, as well as revising and the final approval of the article.
Competing interests OS: consultant for Novartis (Basel, Switzerland), BayerShering-Pharma (Berlin, Germany), Allergan (Irvine, California, USA), Optovue (Freemont, California, USA). ES: consultant for Novartis (Basel, Switzerland), Bayer Shering-Pharma (Berlin, Germany), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France).
Ethics approval Université Paris Est Créteil Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.